said on Monday that it had received tentative U.S. Food and Drug Administration approval for a generic treatment designed to prevent heart attacks and strokes.
The drug company's Pravastatin tablets are a generic version of
Pravachol, which had U.S. sales of about $1.3 billion in 2001.
The company plans to offer the treatment in 10-milligram, 20-mg, and 40-mg tablets.
Shares of Teva were up about 1.2% to $63.35 on the news in premarket trading after closing at $62.60 Friday.